MedTrace Logo

A Study to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone

NCT02730689 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2016-04-06

No results posted yet for this study

Summary

The purpose of this study is to compare the pharmacokinetics of DP-R207 (Rosuvastatin 10mg and Ezetimibe 10mg fixed dose combinations) in comparison to each component administered alone in health male volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

DP-R207

DRUG

Rosuvastatin

DRUG

Ezetimibe

Sponsors & Collaborators

  • Alvogen Korea

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-01-31
Completion
2015-01-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02730689 on ClinicalTrials.gov